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Introduction
The application of in vitro approaches to predict drug disposition parameters in humans has found widespread acceptance over the last two decades (Houston, 1994; Ito et al., 1998; Obach, 1999; Riley et al., 2005; Hosea et al., 2009; Lave et al., 2009 ). In particular, in vitro-in vivo extrapolation has been used to predict clearance and drug-drug interaction potential for hepatically cleared compounds Miners et al., , 2010 Lave et al., 2009) . Most commonly, in vitro intrinsic clearance for a pathway (CL int ), typically determined using human liver microsomes (HLMs) or hepatocytes as the enzyme source, is extrapolated to hepatic clearance and extraction ratio using appropriate scaling and physiological modeling procedures. CL int may be calculated from the measurement of product formation under initial rate conditions (as V max / K m ), or from the rate of substrate depletion. Likewise, extrapolation of an inhibitor constant (K i ) determined in vitro allows prediction of the magnitude of an inhibitory drug-drug interaction (Ito et al., 1998 (Ito et al., , 2004 Miners et al., 2010) .
However, hepatic clearance and drug-drug interaction potential are frequently underpredicted (Ito and Houston, 2005; Miners et al., 2006) . Numerous methodological issues contribute to the accuracy of predicted disposition parameters (Hallifax and Houston, 2009; Miners et al., 2010) . Notably, nonspecific binding (NSB) of a drug to the in vitro enzyme source, especially HLMs, decreases the availability of unbound drug in the incubation medium [f u(mic) ] for metabolism (Obach, 1997; McLure et al., 2000; Venkatakrishnan et al., 2000; Austin et al., 2002; Margolis and Obach, 2003) . Thus, K m and K i values are overestimated, resulting in underestimation of predicted hepatic clearance and magnitude of an inhibitory drug-drug interaction. Furthermore, complex effects on reaction kinetics may be observed when substrate concentrations are in the saturable binding range (McLure et al., 2000) .
Measurement of f u(mic) and correction for binding is therefore essential for the calculation of in vitro kinetic parameters. Equilibrium dialysis and ultrafiltration are the most commonly used experimental techniques for the determination of f u(mic) , and hence measurement of this parameter can be onerous, especially early in preclinical drug development (Grime and Riley, 2006) . Algorithms based on published or in-house databases have been reported (Austin et al., 2002; Hallifax and Houston, 2006; Sykes et al., 2006; Gao et al., 2008; Kilford et al., 2008; Li et al., 2009) , although most consider only charge state and lipophilicity as variables.
Fluorescent probes provide an alternative approach to the measurement of drug binding to HLMs and other membranes. 1-Anilinonaphthalene-8-sulfonate (ANS) binds noncovalently to the polar head groups of phosphatidylcholine present in membranes with negligible disruption of bilayer structure (Slavik, 1982) . More importantly, ANS fluorescence is inversely proportional to the negative surface potential of the membrane (Slavik, 1982) . Thus, the binding of cations to phosphate and carboxyl groups, which decreases surface electrostatic potential, facilitates ANS binding and fluorescence (Slavik, 1982) . Consistent with the known effects of membrane charge on ANS fluorescence, it has been demonstrated that several drugs that are positively charged at physiological pH enhance the fluorescence of microsome-bound ANS, whereas negatively charged drugs decrease the fluorescence of ANS in the presence of microsomes (Diaugustine et al., 1970; Hawkins and Freedman, 1973; Birkett, 1974) . These data suggest that drug-induced shifts in baseline ANS fluorescence may provide a measure of the NSB of drugs to HLMs.
Drug binding to the membranes seems to be primarily dependent on charge state and lipophilicity (measured as log P or log D), as might be predicted from passive partitioning into the phospholipid bilayer (Herbette et al., 1983; Austin et al., 2005; Nussio et al., 2007) . Evidence, to date, indicates that NSB is greatest for lipophilic organic bases (McLure et al., 2000; Austin et al., 2002; Sykes et al., 2006) and is thought to arise from favorable electrostatic interactions with negatively charged phosphate head groups while orienting lipophilic groups along the hydrocarbon chains of the bilayer. In contrast, neutral and acidic compounds bind less extensively or not at all. As noted above, most algorithms for the prediction of f u(inc) therefore consider only log P and charge state at pH 7.4 as variables, although more recent analyses suggest a role for electrostatic features (Li et al., 2009) .
Here, we investigated the relationship between the binding of drugs to HLMs as measured by equilibrium dialysis (f u(mic) ) and the magnitude of the change induced in baseline ANS fluorescence. The results demonstrate that the ANS fluorescence technique provides a simple and convenient method for estimating f u(mic) and additionally provides further insights into the physicochemical features of drugs that contribute to membrane binding.
Materials and Methods
Materials. ANS, bupropion hydrochloride, chloroquine diphosphate, chlorpromazine hydrochloride, imipramine hydrochloride, lignocaine hydrochloride monohydrate, propranolol hydrochloride, and triflupromazine hydrochloride were purchased from Sigma-Aldrich (Sydney, Australia). Other drugs were kindly provided by the following sources: atenolol, bupivacaine hydrochloride, and ropivacaine hydrochloride from AstraZeneca (Sydney, Australia); diazepam from F. Hoffmann-La Roche (Basel, Switzerland); diflunisal from Merck Sharp and Dohme (Sydney, Australia); flufenamic acid and meclofenamic acid from Parke-Davis and Company (Sydney, Australia); mianserine hydrochloride from Organon (Sydney, Australia); and verapamil hydrochloride from Knoll Australia (Sydney, Australia).
Human Liver Microsomes. NSB experiments were performed with pooled microsomes from two human livers obtained from the human liver bank of the Department of Clinical Pharmacology at Flinders Medical Centre. Donors of the respective livers were a 49-year-old female and a 22-year-old male. Neither was a cigarette smoker; however, both received dopamine before their death. Approval was obtained from the Flinders Clinical Research Ethics Committee for the use of human liver tissue in drug disposition studies in vitro. HLMs were prepared according to the general procedure of Bowalgaha et al. (2005) .
Equilibrium Dialysis. Direct measurement of the binding of drugs to HLMs was performed with an equilibrium dialysis apparatus (Dianorm, Munich, Germany) containing Teflon dialysis cells of 1.2-ml capacity per side, using a working volume of 1 ml. Spectra/Por #4 dialysis membrane (molecular mass cut off 12,000 -14,000 Da) was purchased from Spectrum Medical Industries Inc. (Los Angeles, CA) and prepared by soaking overnight in phosphate buffer (PB; 0.1 M, pH 7.4) at 4°C before dialysis experiments. Each of the drugs was diluted 1:100 upon addition to the dialysis cell to give the concentration required. PB (0.99 ml; 0.1 M, pH 7.4) and a 0.01-ml aliquot of the test drug were loaded into one side of each dialysis cell. A suspension of HLMs in PB (1 ml; protein concentration, 1 mg/ml) was added to the other side of the dialysis cell. The dialysis cell assembly was immersed in a water bath maintained at 37°C and rotated at 12 rpm for 3 h. After dialysis, each side of the cell was unloaded by expelling the contents into a 5-ml glass tube. A negative control and HLM-HLM and PB-PB controls were used in each dialysis experiment. The negative control comprised PB (1 ml; 0.1 M, pH 7.4) without drug on one side of the dialysis cell and a suspension of HLMs in PB (1 ml; protein concentration, 1 mg/ml) on the other side. HLM-HLM controls consisted of a suspension of HLMs (0.99 ml; protein concentration, 1 mg/ml) and a 0.01-ml aliquot of the test drug at a "mid" concentration of the range used in binding experiments with a suspension of HLMs (1 ml; protein concentration, 1 mg/ml) in the other side of the dialysis cell. PB was substituted for HLMs in the PB-PB control samples.
Sample Preparation and HPLC Conditions. Drug concentrations in the buffer and microsome compartments of the dialysis cell were measured by HPLC. Before chromatography, all samples were treated with acetonitrile or mixtures containing acetonitrile (plus internal standard, with the exception of imipramine) to precipitate microsomal protein. After dilution, samples were vortex mixed for 10 s and centrifuged at 2000g for 10 min at 4°C. An aliquot of the supernatant fraction was injected onto the HPLC column. The sample preparation procedure for each drug is summarized in Table 1. HPLC assays were developed and validated for each drug investigated in dialysis experiments. The mobile phase, column type, detector wavelength, and retention time of the analyte and the internal standard are shown in Table 2 . The mobile phase flow rate was 1 ml/min for all analytes, except flufenamic acid (1.5 ml/min). Unknown concentrations were determined by reference of peak height ratios (drug to internal standard) to those of a standard curve that spanned the concentration range of the drug recovered from the separate buffer and HLM compartments of the dialysis cell. All standard curves were linear with r 2 values Ն0.990. Calculation of f u(mic) and Log P. The binding of drugs to HLMs is expressed as the unbound fraction of drug in the microsomal suspension [i.e., f u(mic) ], giving a value between 0 and 1. Thus, f u(mic) was calculated as the proportion of free drug (i.e., concentration in the buffer compartment) to free plus bound drug (i.e., concentration in the microsome compartment) according to eq. 1:
Values of f u(mic) determined in the presence of either 0.25 or 1 mg/ml HLM were interconverted according to eq. 2 (Austin et al., 2002) : Table 2 .
where C 1 and C 2 are the two concentrations of HLM and f u(mic)1 and f u(mic)2 are the unbound fractions at the two HLM concentrations. Log P values were calculated computationally using SciFinder (American Chemical Society, Columbus, OH) using Advanced Chemistry Development Software version 4.64 for Solaris (ACD Labs, Toronto, Canada). ANS Fluorescence Assay. Aliquots (10 l) of separate 20 mM stock solutions of each test drug were added to 2 ml of PB containing ANS (10 M) and HLMs (0.25 mg/ml) in a 4.5-ml glass cuvette to produce drug concentrations ranging from 100 to 1000 M. Drugs were dissolved in water, except for diazepam (methanol) and itraconazole (dimethyl sulfoxide). Neither methanol nor dimethyl sulfoxide, at a concentration of 0.5% v/v, affected ANS fluorescence. ANS fluorescence, recorded before and after addition of the drug, was measured using a 3000 Fluorescence Spectrometer (PerkinElmer Life and Analytical Sciences, Waltham, MA). The ANS excitation and emission wavelengths were 375 and 470 nm, respectively (Molecular Probes, Leiden, Netherlands). All measurements were performed at least in duplicate. The occurrence of quenching was excluded for all drugs. Percentage fluorescence increment or decrement in ANS fluorescence due to added drug was calculated according to Birkett (1974) 
Results
Equilibrium Dialysis. Table 3 shows log P, pK a , and microsomal nonspecific binding data, determined using equilibrium dialysis, for the compounds studied here. Nonspecific binding was determined at three drug concentrations (100, 200, and 500 M), and results are presented as f u(mic) . The lipophilic acidic drugs diflunisal, flufenamic acid, and meclofenamic acid all bound to HLMs, and f u(mic) values tended to decrease with increasing log P. Atenolol, the most hydrophilic base investigated, did not bind to HLMs. Likewise, neither lignocaine nor the structurally related amide local anesthetic agents bupivacaine and ropivacaine, which exhibit log P values in the range 2.4 to 3.6, bound to HLMs. Bupropion was also found not to bind to HLMs. Chloroquine and verapamil bound moderately [f u(mic) Ն 0.70], whereas chlorpromazine, imipramine, mianserine, propranolol, and triflupromazine bound more extensively (f u(mic) Յ 0.60). The neutral drug diazepam bound moderately [f u(mic) 0.76 -0.77] to HLMs.
ANS Fluorescence. The percentage ANS fluorescence increment/ decrement was used as the measure of ANS fluorescence as this parameter represents the change from baseline (microsomes plus ANS) due to the effect of added drug. The background fluorescence of drug in the experimental matrix was accounted for in the calculation of percentage ANS fluorescence increment/decrement. None of the drugs investigated exhibited quenching. Three basic drugs, imipramine, lignocaine, and propranolol, were selected initially to characterize effects on ANS fluorescence in the presence of HLMs. Imipramine and propranolol caused concentrationdependent increases in ANS fluorescence over the concentration range tested, and the effects on ANS fluorescence were saturable (Table 4 ; Fig. 1 ). Consistent with the equilibrium binding data, ANS fluorescence was essentially unaltered by lignocaine (Table 4) .
Other drugs characterized for nonspecific binding to HLMs using equilibrium dialysis were subsequently investigated using the ANS fluorescence technique at concentrations of 100, 200, and 500 M. Results are shown in Table 5 . The acidic drugs (diflunisal, flufenamic acid, and meclofenamic acid) and the neutral drug diazepam caused a concentration-dependent decrease in ANS fluorescence in the presence of HLMs. With the exception of the anomalous result for bupropion, basic compounds were without effect (atenolol, bupivacaine, lignocaine, and ropivacaine) or caused an increase (chloroquine, chlorpromazine, imipramine, mianserine, propranolol, triflupromazine, and verapamil) in ANS fluorescence in the presence of HLMs.
Equilibrium dialysis experiments were performed at a microsomal protein concentration of 1 mg/ml, whereas the maximum HLM protein concentration that could be used in ANS fluorescence experiments, due to matrix turbidity, was 0.25 mg/ml. Thus, f u(mic) values determined using equilibrium dialysis were converted to a HLM protein concentration of 0.25 mg/ml using an expression derived and validated by Austin et al. (2002) (see eq. 2 under Materials and Methods). Derived f u(mic) values were plotted against the modulus (i.e., absolute value without regard to sign) of the percentage ANS fluorescence increment/decrement (Fig. 2) . Data were also plotted as log(1 Ϫ f u(mic) /f u(mic) ) versus the modulus of percentage ANS fluorescence increment/decrement. Linear and highly significant relationships ( p Ͻ 0.001; Fig. 2) were observed between the modulus of percentage ANS fluorescence increment/decrement and f u(mic) (y ϭ Ϫ149x ϩ 152; r ϭ 0.93) and log{(1 Ϫ f u(mic) )/f u(mic) }(y ϭ 47x ϩ 72; r ϭ 0.85). Highly significant relationships ( p Ͻ 0.001) were also evident at higher drug concentrations. Expressions for the relationships between the modulus of percentage ANS fluorescence increment/decrement and f u(mic) were y ϭ Ϫ258x ϩ 268 (r ϭ 0.96) and y ϭ Ϫ604x ϩ 621 (r ϭ 0.90) at drug concentrations of 200 and 500 M, respectively. For the relationship between the modulus of percentage ANS fluorescence increment/decrement and log{(1 Ϫ f u(mic) )/ f u(mic) }, expressions were y ϭ 81x ϩ 128 (r ϭ 0.94) at 200 M and y ϭ 170 ϩ 273 (r ϭ 0.85) at 500 M. Because the correlations shown in Fig. 2 are for a HLM concentration of 0.25 mg/ml, values of f u(mic) are lower than at the usual HLM concentration used in NSB studies (namely, 1 mg/ml). As shown in Table 3 , the f u(mic) range at an HLM concentration of 1 mg/ml is 0.08 to 1.
For validation, the ANS fluorescence increment/decrement was measured for five compounds characterized previously using equilibrium dialysis in this laboratory (namely amitriptyline, nortriptyline, phenytoin, S-naproxen, and lamotrigine) (McLure et al., 2000; Rowland et al., 2006) and for itraconazole (see Tables 1 and 2 for equilibrium dialysis sample workup and HPLC conditions for itraconazole). ANS fluorescence data for these compounds are shown in Table 6 , and predicted and reported f u(mic) values from equilibrium dialysis are shown in Table 7 .
Discussion
Consistent with previous reports (Diaugustine et al., 1970; Hawkins and Freedman, 1973; Birkett, 1974) , ANS fluorescence was enhanced by basic drugs that bound to HLMs, whereas acidic drugs and the neutral compound diazepam caused a decrease in ANS fluorescence. More importantly, there was a highly significant linear relationship between f u(mic) and the modulus of the fluorescence increment or decrement for the combined data set at each added drug concentration. The relationship between the change in ANS fluorescence and log{(1 Ϫ f u(mic) )/f u(mic) }, which is similar to an equilibrium constant and is considered a more appropriate expression when dealing with linear free energy relationships (Austin et al., 2002) , was also linear and highly statistically significant. Together, these data indicate that changes in ANS fluorescence may be used to estimate the NSB of drugs to HLMs.
The basic drugs shown here to bind to HLMs using equilibrium dialysis (chloroquine, chlorpromazine, imipramine, mianserine, propranolol, triflupromazine, and verapamil) all increased ANS fluorescence. Consistent with NSB data generated from equilibrium dialysis (McLure et al., 2000) , the increase in ANS fluorescence observed with imipramine and propranolol was saturable over the concentration range 100 to 1000 M (Fig. 1) . In contrast, no change from baseline fluorescence was observed for those basic drugs (atenolol, bupiva- caine, lignocaine, and ropivacaine) shown not to bind to HLMs using equilibrium dialysis. In contrast, the three acidic drugs diflunisal, flufenamic acid, and meclofenamic acid, along with the neutral diazepam, decreased ANS fluorescence compared to baseline. The only exception to this trend was observed with bupropion. This nonbinding basic compound caused a decrease in ANS fluorescence. The reason for this anomalous result is unclear but may be due to the presence of an acidic side-chain carbon atom located between electron-withdrawing nitrogen and carbonyl functions, which may cause bupropion to act more as an acid than a base with respect to NSB. ANS fluorescence data for amitriptyline, itraconazole, lamotrigine, nortriptyline, phenytoin, and S-naproxen were generated for validation of the procedure. Amitriptyline, itraconazole, and nortriptyline are bases that exhibit moderate to high binding to HLMs, whereas lamotrigine, phenytoin, and S-naproxen are acids that bind negligibly or weakly to HLMs. The NSB of amitriptyline, lamotrigine, nortriptyline, phenytoin, and S-naproxen to HLMs has been characterized previously in this laboratory by equilibrium dialysis (McLure et al., 2000; Rowland et al., 2006) , and additional data were generated here for itraconazole. ANS fluorescence was enhanced by amitriptyline, itraconazole, and nortriptyline, whereas addition of lamotrigine, phenytoin, or S-naproxen to a suspension of HLMs was without effect or caused a small decrease in ANS fluorescence. More importantly, there was good agreement between the f u(mic) values predicted for each drug from the ANS fluorescence increment/decrement and that determined directly by equilibrium dialysis ( Table 7) .
The NSB data presented here are generally consistent with the principle that extensive NSB is associated with lipophilic organic bases. However, some observations warrant comment. Notably, the NSB of chloroquine (log P ϭ 4.9) was low (f u(mic) Ն 0.78) across the concentration range investigated. The binding of mianserine (log P ϭ 3.4) exceeded that of the more lipophilic bases chloroquine and imipramine (log P ϭ 4.8). In contrast, bupivacaine and bupropion, which have similar log P values to mianserine (namely 3.5 and 3.6, respectively), did not bind to HLMs. Two other local anesthetics structurally related to bupivacaine, lignocaine (log P ϭ 2.4), and ropivacaine (log P ϭ 3.1) also exhibited negligible NSB. Although most acidic drugs investigated to date bind minimally to HLMs (Obach, 1997; McLure et al., 2000; Austin et al., 2002; Li et al., 2009 ), 30 to 40% binding was observed for flufenamic acid and meclofenamic acid. Together, these data indicate that factors other than charge state and log P influence the degree of NSB. In this regard, recent computational modeling studies have implicated prop- erties such as polar surface area as determinants of NSB, although lipophilicity was the most important descriptor (Gao et al., 2008; Li et al., 2009 ). Compounds containing a halogen atom(s) (e.g., flufenamic acid, meclofenamic acid, chlorpromazine, itraconazole, triflupromazine) also seem to be more likely to exhibit significant NSB. Other factors that potentially affect the extent of NSB include molecular mass (organic bases with molecular masses Ͼ200 Da seem more likely to exhibit significant NSB compared with compounds with lower molecular masses), charge distribution, and the number of hydrogen bond acceptors/donors (J. O. Miners and J. A. McLure, unpublished data) . However, exceptions occur. For example, itraconazole, a compound shown here to bind extensively to HLMs, has 14 hetero-atoms (although two of these are chlorines; see above discussion).
The NSB of chlorpromazine, diazepam, imipramine, propranolol, and verapamil has also been reported by Austin et al. (2002) . Values of f u(mic) determined here and reported by Austin et al. (2002) were similar for chlorpromazine [f u(mic) The previous study used rat liver microsomes (1 mg/ml) and a drug concentration of 1 M, whereas the current study used HLMs (1 mg/ml) and drug concentrations ranging from 100 to 500 M. The lower NSB sometimes observed at high drug concentrations may contribute to the observed differences.
Limitations of the ANS fluorescence method for the determination of NSB are acknowledged. As noted previously, the highest concentration of microsomes that can be used is 0.25 mg/ml because of the effects of matrix turbidity on ANS fluorescence. Changes in ANS fluorescence generally are not detectable for added drug concentrations below 25 to 50 M, and the method has not been investigated for HLM protein concentrations Ͻ0.25 mg/ml. Whether sensitivity can be improved with fluorescent probes other than ANS, of which many are commercially available, is currently under investigation. It is also acknowledged that data presented here report NSB for microsomes from only two livers. However, experience in this laboratory demonstrates that f u(mic) values differ to a very minor extent (Ͻ5%) for microsomes prepared from the livers of multiple donors (J. O. Miners, unpublished data). Indeed, lack of an appreciable difference in drug binding to hepatic microsomes across a range of mammalian species (human, monkey, dog, and rat) has recently been reported (Zhang et al., 2010) .
In summary, this study reports "proof-of-principle" evidence that the fluorescent probe ANS provides an accurate, simple, and potentially high throughput method for measuring the NSB of drugs and other compounds to HLMs. In particular, there were highly significant linear relationships between the modulus of the increment/decrement in ANS fluorescence and both f u(mic) and log(1 Ϫ f u(mic) /f u(mic) ), and agreement between measured f u(mic) and that predicted by ANS fluorescence was very good for a validation set of six compounds. The microsomal binding data reported here further demonstrate that physicochemical properties other than charge and lipophilicity (as log P) influence NSB. 
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